Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's CRI launches two clinical trials targeting cancers

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8

Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announces positive clinical data of ISF35 with chemotherapy

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

CAM314 randomized Phase 3 clinical trial results released

CAM314 randomized Phase 3 clinical trial results released

Phase 1 study results of TRU-016 in patients with CLL announced

Phase 1 study results of TRU-016 in patients with CLL announced

IMF to stage presentation on multiple myeloma at ASH annual meeting

IMF to stage presentation on multiple myeloma at ASH annual meeting

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders

Discovery holds promise in fighting cancer, AIDS and autoimmune disorders

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

Genetic identity of cellular receptor for the immune system's first-response antibody discovered

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.